Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with > 1 year prior ibrutinib exposure
Authors
Rawstron, AMunir, T
Brock, K
Webster, N
Vicente, M
Yates, F
Cramp, S
Bishop, R
Dalal, S
De Tute, M
Sheehy, O
Pettitt, A
Fox, P
Devereux, S
Fegan, C
Macdonald, D
Bloor, Adrian
Hillmen, P
Affiliation
Department of Hematology and Medical Oncology, Emory University, Atlanta, GAIssue Date
2018
Metadata
Show full item recordCitation
Rawstron A, Munir T, Brock K, Webster N, Vicente S, Yates F, et al. Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-181Additional Links
https://dx.doi.org/10.1182/blood-2018-181Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-181